Actively Recruiting
Study of GT103 and Pembrolizumab for Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Led by Roswell Park Cancer Institute · Updated on 2026-08-19
28
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well the anti-CFH monoclonal antibody GT103 combined with pembrolizumab works in treating patients with advanced or metastatic STK11 mutant non-small cell lung cancer NSCLC. This phase II trial focuses on patients whose cancer has spread locally or to distant parts of the body and aims to assess progression-free survival and other clinical outcomes. The study also explores how this combination affects the tumor environment and investigates potential biomarkers that might predict treatment response. Participants receive GT103 intravenously over 60 minutes and pembrolizumab intravenously over 30 minutes on the first day of each 21-day cycle. Treatment may continue for up to two years unless the disease progresses or unacceptable side effects occur. Throughout the study, patients undergo various assessments including echocardiography, magnetic resonance imaging, computed tomography scans, blood sample collections, and possibly tumor biopsies to monitor the disease and treatment effects. During the trial, participants are closely monitored with scheduled imaging and laboratory tests to evaluate cancer progression, response to treatment, and safety. After completing treatment, patients have follow-up visits every 30 days for four months. The main outcome measured is progression-free survival up to six months, while secondary outcomes include overall survival, response rates, duration of response, disease control, and adverse events. This comprehensive monitoring helps researchers understand the treatments impact and safety over time.
CONDITIONS
Brief Title
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here